Waltham-based medical technology company Augmenix Inc. said today it has received clearance from the U.S. Food and Drug Administration to market its TraceIT Tissue Marker, which is used to radiographically mark soft tissue during surgical procedures.

Augmenix, a privately held company founded in 2008, is focused on utilizing hydrogel technology in the fields of tissue marking and radiation oncology.

The article you requested has been archived

All coverage within bostonherald.com from the last 14 days remains free of charge. Articles do not always include original photos, charts or graphics.